Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland’s Novartis works to enhance its investor appeal ahead of its market debut next month.

Bringing a drug to market is harder than ever, and manufacturers continue to navigate a complex road to get therapies to patients. On average, manufacturers spend more than $125 million over the three years leading up to launch, yet two-thirds of drugs fail to meet launch expectations.

Optimizing product launches has never been more challenging or more vital. The challenges of stiff competition, a shift toward more specialty drugs with smaller patient populations, restricted physician access, and the growing influence of payers, make it essential for launch teams to be as strategic and efficient as possible.

Fishawack Health welcomes an experienced executive who will foster business development partnerships to meet clients’ commercialization needs.

Unlike their Big Pharma cousins, most start-ups just don’t have the same level of launch experience, and they also lack much of the key infrastructure taken for granted in the top ten organizations; and of course launch revenue is critical for a fledgling company.

Encompassing two healthcare agencies, a full-service production studio and new media services group, the corporate group is poised for continuing growth.

Klick Group announced today that longtime McKinsey & Company executive Brian C. Fox has joined as President to help lead the company’s growth as the premier provider of end-to-end commercialization services for life sciences companies. Fox brings deep expertise in market strategy, product launches, sales force effectiveness, medical affairs, market access, clinical development, and corporate affairs.

Leo Tarkovsky brings more than 25 years of proven experience scaling companies in the healthcare space.

CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide for subcutaneous injection that comes in a pre-filled syringe with no mixing required. Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., is heading distribution in the United States.

Med Ad News sits down with Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories. He has more than 20 years of experience in the pharmaceutical industry with extensive knowledge and understanding of generics.